Intranasal delivery of an IgA monoclonal antibody effective against sublethal H5N1 influenza virus infection in mice

Clinical and Vaccine Immunology

Volumn 17, Issue 9, 2010, Pages 1363-1370

  Ye, Jianqiang ^a   Shao, Hongxia ^a,b   Hickman, Danielle ^a   Angel, Matthew ^a   Xu, Kemin ^a   Cai, Yibin ^a   Song, Haichen ^c   Fouchier, Ron A M ^d   Qin, Aijian ^b   Perez, Daniel R ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b YANGZHOU UNIVERSITY   (China)

^c ZOETIS   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DPJY01; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN A; IMMUNOTHERAPY; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 77956410594     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00002-10     Document Type: Article

References (39)

1. Abdel-Ghafar, A. N., T. Chotpitayasunondh, Z. Gao, F. G. Hayden, D. H. Nguyen, M. D. de Jong, A. Naghdaliyev, J. S. Peiris, N. Shindo, S. Soeroso, and T. M. Uyeki. 2008. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358:261-273.
2. Armstrong, S. J., and N. J. Dimmock. 1992. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J. Virol. 66:3823-3832.
3. Beigel, J. H., J. Voell, C. Y. Huang, P. D. Burbelo, and H. C. Lane. 2009. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J. Infect. Dis. 200:501-509.
4. Chen, Y., K. Qin, W. L. Wu, G. Li, J. Zhang, H. Du, M. H. Ng, J. W. Shih, J. S. Peiris, Y. Guan, H. Chen, and N. Xia. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49-58.
5. Chokephaibulkit, K., M. Uiprasertkul, P. Puthavathana, P. Chearskul, P. Auewarakul, S. F. Dowell, and N. Vanprapar. 2005. A child with avian influenza A (H5N1) infection. Pediatr. Infect. Dis. J. 24:162-166.
6. Cram, P., S. G. Blitz, A. Monto, and A. M. Fendrick. 2001. Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmacoeconomics 19:223-230.
7. de Jong, M. D., T. T. Tran, H. K. Truong, M. H. Vo, G. J. Smith, V. C. Nguyen, V. C. Bach, T. Q. Phan, Q. H. Do, Y. Guan, J. S. Peiris, T. H. Tran, and J. Farrar. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
8. Gillissen, A., and G. Hoffken. 2002. Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment. Med. Microbiol. Immunol. 191:165-168.
9. Hanson, B. J., A. C. Boon, A. P. Lim, A. Webb, E. E. Ooi, and R. J. Webby. 2006. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir. Res. 7:126.
10. Hayden, F. G. 2006. Antiviral resistance in influenza viruses - implications for management and pandemic response. N. Engl. J. Med. 354:785-788.
11. Lamb, R. A. 1989. Genes and proteins of the influenza viruses. In R. M. Krug (ed.), The influenza viruses, 1st ed. Plenum Press, New York, NY.
12. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
13. Liem, N. T., C. V. Tung, N. D. Hien, T. T. Hien, N. Q. Chau, H. T. Long, N. T. Hien, Q. Mai le, W. R. Taylor, H. Wertheim, J. Farrar, D. D. Khang, and P. Horby. 2009. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin. Infect. Dis. 48:1639-1646.
14. Lipatov, A. S., A. K. Gitelman, and Y. A. Smirnov. 1997. Prevention and treatment of lethal influenza A virus bronchopneumonia in mice by monoclonal antibody against haemagglutinin stem region. Acta Virol. 41:337-340.
15. Luke, T. C., E. M. Kilbane, J. L. Jackson, and S. L. Hoffman. 2006. Metaanalysis. Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145:599-609.
16. Nolan, T. M., P. C. Richmond, M. V. Skeljo, G. Pearce, G. Hartel, N. T. Formica, K. Hoschler, J. Bennet, D. Ryan, K. Papanaoum, R. L. Basser, and M. C. Zambon. 2008. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26:4160-4167.
17. Park, J. W., and W. H. Jo. 2009. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir. J. Chem. Inf. Model. 49:2735-2741.
18. Prabakaran, M., N. Prabhu, F. He, Q. Hongliang, H. T. Ho, J. Qiang, T. Meng, M. Goutama, and J. Kwang. 2009. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4:e5672.
19. Prabhu, N., M. Prabakaran, H. T. Ho, S. Velumani, J. Qiang, M. Goutama, and J. Kwang. 2009. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 83:2553-2562.
20. Prabhu, N., M. Prabakaran, Q. Hongliang, F. He, H. T. Ho, J. Qiang, M. Goutama, A. P. Lim, B. J. Hanson, and J. Kwang. 2009. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Antivir. Ther. 14:911-921.
21. Reece, P. A. 2007. Neuraminidase inhibitor resistance in influenza viruses. J. Med. Virol. 79:1577-1586.
22. Reed, L. J., and H. Muench. 1938. A simple method for estimating 50 percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
23. Shun-Shin, M., M. Thompson, C. Heneghan, R. Perera, A. Harnden, and D. Mant. 2009. Neuraminidase inhibitors for treatment and prophylaxis of in- fluenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339:b3172.
24. Simmons, C. P., N. L. Bernasconi, A. L. Suguitan, K. Mills, J. M. Ward, N. V. Chau, T. T. Hien, F. Sallusto, D. Q. Ha, J. Farrar, M. D. de Jong, A. Lanzavecchia, and K. Subbarao. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178.
25. Song, H., G. R. Nieto, and D. R. Perez. 2007. A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J. Virol. 81:9238-9248.
26. Suguitan, A. L., Jr., M. P. Marino, P. D. Desai, L. M. Chen, Y. Matsuoka, R. O. Donis, H. Jin, D. E. Swayne, G. Kemble, and K. Subbarao. 2009. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 395:280-288.
27. Sui, J., W. C. Hwang, S. Perez, G. Wei, D. Aird, L. M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N. J. Cox, L. A. Bankston, R. O. Donis, R. C. Liddington, and W. A. Marasco. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
28. Sun, L., X. Lu, C. Li, M. Wang, Q. Liu, Z. Li, X. Hu, J. Li, F. Liu, Q. Li, J. A. Belser, K. Hancock, Y. Shu, J. M. Katz, M. Liang, and D. Li. 2009. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476.
29. Tamura, S., and T. Kurata. 2004. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn. J. Infect. Dis. 57:236-247.
30. Throsby, M., E. van den Brink, M. Jongeneelen, L. L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, J. Cinatl, J. ter Meulen, I. Lasters, R. Carsetti, M. Peiris, J. de Kruif, and J. Goudsmit. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942.
31. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
32. Webster, R. G., N. J. Cox, and K. Sthor. 2002. WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland.
33. Weltzin, R., and T. P. Monath. 1999. Intranasal antibody prophylaxis for protection against viral disease. Clin. Microbiol. Rev. 12:383-393.
34. White, N. J., R. G. Webster, E. A. Govorkova, and T. M. Uyeki. 2009. What is the optimal therapy for patients with H5N1 influenza? PLoS Med. 6:e1000091.
35. World Health Organization. 2009. Continuing progress towards a unified nomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2.2 viruses. Influenza Other Respir Vir. 3:59-62.
36. World Health Organization. 2008. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Wkly. Epidemiol. Rec. 83:415-420.
37. Yang, M., Y. Berhane, T. Salo, M. Li, K. Hole, and A. Clavijo. 2008. Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. J. Virol. Methods 147:265-274.
38. Yoshida, R., M. Igarashi, H. Ozaki, N. Kishida, D. Tomabechi, H. Kida, K. Ito, and A. Takada. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5:e1000350.
39. Zhou, B., N. Zhong, and Y. Guan. 2007. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357:1450-1451.